RxDoctor Payments Data

Michael Moore, MD

Internal Medicine · Bessemer, ALNPI 1205815214

Payments from drug & device makers

$3,520in general payments, 2019–2025

Across 209 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$801
  • Novo Nordisk$731
  • Novartis$607
  • Amgen$227
  • GSK$225
  • Johnson & Johnson$221
  • plus $707 from 21 others

What the payments were for

  • Food & beverage$3,520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,520 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$21,449
Medicare patients
73
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$173,296
OzempicSemaglutide95$95,662
JardianceEmpagliflozin74$70,154
XareltoRivaroxaban71$54,632
JanuviaSitagliptin Phosphate60$49,737
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr67$35,824
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$31,907
Tresiba Flextouch U-200Insulin Degludec36$29,864
Tresiba Flextouch U-100Insulin Degludec49$22,477
EntrestoSacubitril/Valsartan26$13,823
Lantus SolostarInsulin Glargine,hum.Rec.Anlog101$13,383
Atorvastatin Calcium531$6,609
Pravastatin Sodium176$5,234
Losartan Potassium355$5,182
Levothyroxine Sodium245$3,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$801$176,626246 claims
Novo NordiskOzempic$731$95,66295 claims
Boehringer IngelheimJardiance$24$70,15474 claims
GSKAnoro Ellipta, Trelegy Ellipta$225$67,731110 claims
Johnson & JohnsonXarelto$221$54,63271 claims
MerckJanuvia$44$49,73760 claims
NovartisEntresto$607$13,82326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Bessemer

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →